Torii Pharmaceutical Co (TSE:4551) ROCE % : 3.86% (As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Torii Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Torii Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 3.86%.

Torii Pharmaceutical Co ROCE % Historical Data

The historical data trend for Torii Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Torii Pharmaceutical Co ROCE % Chart

Torii Pharmaceutical Co Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

36.96

3.65

4.06

4.79

4.63

Torii Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-1.36	6.54	5.93	7.59	3.86

Torii Pharmaceutical Co ROCE % Calculation

Torii Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	5593	/	( ( (133689 - 13221)	+	(133432 - 12504) )	/ 2 )
	=	5593	/	( (120468	+	120928)	/ 2 )
	=	5593	/	120698
	=	4.63 %

Torii Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	4640	/	( ( (133432 - 12504)	+	(132947 - 13181) )	/ 2 )
	=	4640	/	( ( 120928	+	119766 )	/ 2 )
	=	4640	/	120347
	=	3.86 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Torii Pharmaceutical Co (TSE:4551) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Torii Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Torii Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Torii Pharmaceutical Co (TSE:4551) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Torii Pharmaceutical Co Ltd (TSE:4551) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Torii Nihonbashi Buildingg, 4-1, Nihonbashi-Honcho, 3-chome, Chuo-ku, Tokyo, JPN, 103-8439

Website

http://www.torii.co.jp

Torii Pharmaceutical Co Ltd is a major drug manufacturing company. The company utilizes strategic partnerships with other pharmaceutical companies in order to combine research and marketing functions. Torii's key therapeutic areas include renal diseases, hemodialysis, HIV, skin diseases, and allergens. The vast majority of the company's net mainstay product sales are derived from the renal diseases and hemodialysis operations, followed by HIV. Torii's places its strategic focus on prompt market penetration and expansion of new products as well as maximizing values of mainstay products in each priority area.

Torii Pharmaceutical Co (TSE:4551) Headlines

No Headlines